Home » Newsletters » BioWorld

BioWorld

April 4, 1995

View Archived Issues

CEPHALON COMPLETES U.S. PHASE III TRIAL OF MYOTROPHIN

GENENTECH GETS APPROVAL FOR ACCELERATED ACTIVASE INFUSION

OTHER NEWS TO NOTE

HUMAN GENOME SCIENCES AMENDS SMITHKLINE BEECHAM GENOMICS DEAL

OPTIMISM IN EUROPE: BIOTECH EXPANDS, INVESTMENTS IN UK DOUBLE

IMRE RENEGOTIATES PROSORBA DEAL WITH BAXTER, HAS ENOUGH CASH FOR 12

TRANSGENIC MICE LACTATE NORMALLY WHEN HUMAN A-LACTALBUMIN GENE

GENSET COMPLETES FOURTH ROUND OF FINANCING FOR $19.2M

CELLPRO WAITS FOR FURTHER WORD ON $60M DUE FROM CORANGE

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 17, 2024.
Second insulin receptor offers new therapeutic avenues
BioWorld Science
Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.